
Medpace Holdings Retained Earnings | MEDP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -460 M | 8.17 M | -222 M | -360 M | 235 M | 115 M | 68.1 M | -41.5 M | -120 M | -9.58 M | -23 M | -14.3 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 235 M | -460 M | -68.6 M |
Quarterly Retained Earnings Medpace Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -460 M | -511 M | -336 M | -460 M | -596 M | -703 M | -270 M | 8.17 M | 65.6 M | -30.8 M | -119 M | -222 M | -300 M | -371 M | -408 M | -360 M | -380 M | - | -121 M | 235 M | 185 M | 142 M | 159 M | 115 M | 115 M | 115 M | 115 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | -41.5 M | -41.5 M | -41.5 M | -41.5 M | -120 M | -120 M | -120 M | -120 M | -9.58 M | -9.58 M | -9.58 M | -9.58 M | -23 M | -23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 235 M | -703 M | -110 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | ||
|
Renalytix AI plc
RNLX
|
-212 M | - | 5.66 % | $ 22.7 M | ||
|
Meridian Bioscience
VIVO
|
223 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
-584 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
168 M | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
-725 M | - | -11.32 % | $ 1.1 M | ||
|
Brainsway Ltd.
BWAY
|
-98.4 M | $ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
-4.26 B | $ 13.46 | 1.05 % | $ 142 M | ||
|
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
75.7 M | - | - | $ 608 M | ||
|
RadNet
RDNT
|
-95.4 M | $ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
-18.6 M | - | -1.84 % | $ 15.3 M | ||
|
IDEXX Laboratories
IDXX
|
6.39 B | $ 675.24 | -2.09 % | $ 54.3 B | ||
|
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
-498 M | $ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
1.39 B | $ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
1.39 B | $ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
46.9 B | $ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
2.43 B | $ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
-252 M | $ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
-449 M | $ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
-2.99 B | $ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
-720 M | $ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
-335 M | $ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
7.42 B | $ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
-224 M | $ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
9.24 B | $ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
-392 M | $ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
-2.78 B | $ 273.11 | -5.8 % | $ 37.3 B | ||
|
Fulgent Genetics
FLGT
|
530 M | $ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
-735 M | $ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
-56.9 M | $ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
-211 M | $ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
680 M | $ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
-1.02 B | $ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
-532 M | $ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
2.12 B | $ 186.79 | -1.88 % | $ 14.6 B |